Categories: News

Medexus Schedules First Quarter Fiscal 2022 Conference Call

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TORONTO and CHICAGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, August 17, 2021 to discuss the Company’s financial results for the fiscal 2022 first quarter ended June 30, 2021, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along with its MD&A post market on August 16, 2021.

The conference call will be available via telephone by dialing toll free 844-602-0380 for Canadian and U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2010/42339 or on the Company’s Investor Events section of the website: https://www.medexus.com/en_US/investors/news-events.

A webcast replay will be available on the Company’s Investor Events section of the website (https://www.medexus.com/en_US/investors/news-events) through Wednesday, August 17, 2022 A telephone replay of the call will be available approximately one hour following the call, through Tuesday, August 24, 2021 and can be accessed by dialing 877-481-4010 for Canadian and U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 42339.

About Medexus Pharmaceuticals Inc.

Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. The Company has also licensed treosulfan, a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, from medac GmbH for Canada and the United States.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com

Marcel Konrad, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 312-548-3139
E-mail: marcel.konrad@medexus.com

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca

Staff

Recent Posts

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

3 hours ago

CloudWave Ranked #15 on Channel Partners 2025 MSP 501—The Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CloudWave, a leading provider of integrated cybersecurity and cloud infrastructure solutions, has been…

3 hours ago

Availity Applauds Industry Commitment to Modernize Authorizations

Availity’s Intelligent Utilization Management delivers on health plans’ ambitious visionJACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity, the nation’s largest…

3 hours ago

LevelJump Announces 2025 First Quarter Results; Anticipates Revocation of Cease Trade Order

Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…

4 hours ago

Agentic AI Startup VoiceCare AI Completes Successful Funding Round

Company closes $4.54M in Seed round led by Caduceus Capital Partners, with participation from Bread…

4 hours ago

TOBY Urine Test completes participation in 2025 Mayo Clinic and ASU Alliance for Health Care MedTech Accelerator

BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early…

4 hours ago